[REVISION HISTORY]

Advancements in Italian oncology and radiotherapy

Updated 4 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-18 12:34 UTC → 2026-10-07 10:33 UTC · added ~~removed~~

Italian medical institutions continue to advance oncology through specialized training, genomic profiling, and personalized care models. To support genomic cancer profiling for approximately 15,000 eligible patients annually, the University of Milan has launched the second edition of a Level II University Master in ‘Molecular Pathology and Molecular Tumor Board’. This initiative, involving the National Cancer Institute, IEO, Niguarda Cancer Center, and the Lombardy Region, aims to train professionals to translate molecular data into clinical decisions via multidisciplinary teams. In breast cancer care, a gap in genomic testing persists. In 2025, only 9,800 genomic tests were performed for early-stage HR+/HER2- breast cancer, despite an estimated 13,000 eligible patients. Experts from AIOM and Europa Donna Italia stress that integrating these tests into the Essential Levels of Care (LEA) is necessary to reduce regional disparities and bureaucratic hurdles, noting that such tests could reduce chemotherapy use by 48% in specific cases. Newer initiatives are expanding the scope of personalized medicine. The Fondazione per la medicina personalizzata (Fmp) launched ‘Prisma’, a research program seeking to identify a ‘personal code’ for patients to tailor psychological, nutritional, and rehabilitative support. In hematology, the Italian Medicines Agency (AIFA) approved reimbursement for blinatumomab as a first-line treatment for adult patients with newly diagnosed Philadelphia-negative B-cell acute lymphoblastic leukemia, a move that could increase three-year survival rates to over 80%. ~~Additionally, digital tools like the ‘Vita Lmc Tracker’ are being utilized for real-time symptom monitoring~~ This immunotherapy works by creating a direct link between T-lymphocytes and tumor cells to facilitate their destruction. Recent discussions in ~~chronic~~ Rome have also focused on creating an integrated model for accessing innovative therapies for acute myeloid leukemia ~~patients. Concurrently, Italian researchers maintain global leadership in radiotherapy, with Professor Stefano Arcangeli ranking first globally~~ (AML), particularly for ~~prostate cancer hypofractionated radiotherapy research,~~ forms involving the FLT3+ mutation. This model aims to strengthen molecular diagnostics and ~~Giampaolo Montesi contributing~~ ensure uniform access to ~~international standards for image-guided radiotherapy for upper gastrointestinal tumors.~~ specialized care networks.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.